Targets to boost T cell therapies, simultaneous genetic and epigenetic sequencing, and more

Two studies published in Nature Communications reported new strategies and targets that increased the tumor-killing activity of T cell immunotherapies.

By screening epigenetic regulator-targeted small molecules for their effect on T cell cytotoxicity, scientists from Singapore’s Agency for Science, Technology and Research (A*STAR) and colleagues showed inhibition of the histone lysine methyltransferases EHMT1 and EHMT2 increased granzyme expression without terminal T cell differentiation or exhaustion, and enhanced tumor killing by engineered T cells in an orthotopic hepatoblastoma xenograft mouse model...